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Background and aims: Gambling disorder (GD) shares many similarities with substance use disorders (SUDs) in
clinical, neurobiological, and neurocognitive features, including decision-making. We evaluated the relationships
among, GD, decision-making, and brain-derived neurotrophic factor (BDNF), as measured by serum BDNF levels.
Methods: Twenty-one male patients with GD and 21 healthy sex- and age-matched control subjects were evaluated
for associations between serum BDNF levels and the Problem Gambling Severity Index (PGSI), as well as between
serum BDNF levels and Iowa Gambling Task (IGT) indices. Results: The mean serum BDNF levels were
signiﬁcantly increased in patients with GD compared to healthy controls. A signiﬁcant correlation between serum
BDNF levels and PGSI scores was found when controlling for age, depression, and duration of GD. A signiﬁcant
negative correlation was obtained between serum BDNF levels and IGT improvement scores. Discussion: These
ﬁndings support the hypothesis that serum BDNF levels constitute a dual biomarker for the neuroendocrine changes
and the severity of GD in patients. Serum BDNF level may serve as an indicator of poor decision-making
performance and learning processes in GD and help to identify the common physiological underpinnings between
GD and SUDs.
Keywords: gambling disorder, brain-derived neurotrophic factor (BDNF), Iowa Gambling Task (IGT), behavioral
addiction
INTRODUCTION
Gambling disorder (GD), a type of behavioral addiction, is
characterized by persistent and recurrent maladaptive gam-
bling behavior leading to signiﬁcant deleterious legal, ﬁ-
nancial, and psychosocial consequences (Grant, Kim, &
Kuskowski, 2004). GD shares many similar clinical and
neurobiological features with substance use disorders
(SUDs), such as alterations of the mesolimbic dopamine
reward pathway (Potenza, 2008), as well as neurocognitive
features, including impaired decision-making.
Poor performance on the Iowa Gambling Task (IGT),
designed to assess risky decision-making, has been found
consistently among SUDs (Noel, Bechara, Dan, Hanak, &
Verbanck, 2007). Similarly, patients with GD have demon-
strated high risk-taking performance on the task (Lawrence,
Luty, Bogdan, Sahakian, & Clark, 2009). Although the
biological basis for decision-making is poorly understood,
neural systems related to executive function and memory
have been implicated (Brand, Recknor, Grabenhorst, &
Bechara, 2007).
One protein associated with various cognitive func-
tions such as decision-making and memory is the brain-
derived neurotrophic factor (BDNF) (Yamada, Mizuno, &
Nabeshima, 2002). BDNF plays an important role in
neuronal survival, neurogenesis, and synaptic plasticity.
Studies have shown associations between BDNF and
changes in behavior and psychopathology in psychiatric
disorders such as depression, schizophrenia, and bipolar
disorder (Montegia et al., 2007), as well as autism spectrum
disorder (Wang et al., 2015). Increases in serum levels of
BDNF have been observed in drug addictions (Angelucci
et al., 2010), where the involvement of BDNF in the ventral
tegmental area-nucleus accumbens (VTA-NAc)-mediated
processes has been implicated (Pu, Liu, & Poo, 2006).
In contrast, only a few studies have examined the asso-
ciation between BDNF and GD (Angelucci et al., 2013;
Geisel, Banas, Hellweg, & Muller, 2012), and how BDNF
levels relate to the severity of GD and the level of im-
pairment in neurocognitive tasks remains unclear. Reduced
serum BDNF has been found to relate to poor performance
on the IGT (Hori, Yoshimura, Katsuki, Atake, & Nakamura,
2014) and immediate memory (Zhang et al., 2012) in
patients with schizophrenia. Associations between low
BDNF levels and cognitive impairment have been further
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conﬁrmed in a large elderly population (Shimada et al.,
2014).
In this study, we examined the relationships among GD,
BDNF, and decision-making performance on the IGT in a
sample of GD patients and compared the serum BDNF
levels in GD patients with those in healthy control subjects.
We then investigated the association of serum BDNF levels
with the severity of GD and IGT indices.
METHODS
Participants
Twenty-one male patients who fulﬁlled the DSM-5 criteria
for GD were recruited from the outpatient gambling clinic of
the Department of Psychiatry, Gangnam Eulji Hospital,
Eulji University, Korea. The diagnoses were determined
by a board-certiﬁed psychiatrist (SWC) through the
examination of past medical records and a semi-structured
interview that included questions about the presence of co-
occurring disorders. A self-report questionnaire regarding
age, weight, height, alcohol-related history, regular medica-
tion use, gambling-related history, and clinical variables was
also administered. The severity of GD was assessed with the
Problem Gambling Severity Index (PGSI), a nine-item self-
report assessment measure reported to be useful for both
clinical and non-clinical settings (Young & Wohl, 2011).
Mood symptoms were assessed using the Beck Depression
Inventory (BDI). The exclusion criteria for the patient group
were 1) any history of a chronic physical disease, 2) regular
use of any medication, and 3) presence of comorbid
psychiatric disorders, including alcohol and nicotine depen-
dence. The control group consisted of 21 age- and
sex-matched healthy male volunteers who had no current
or past psychiatric history or history of medication use.
Measures
Measurement of serum BDNF levels. A total of 10 ml of
blood was drawn from each subject into a serum separator
tube. Samples were allowed to clot for 30 minutes before
centrifugation for 15 min at approximately 1000 g, after
which the serum was removed. All samples were stored at
−80 °C. The serum BDNF levels were determined using an
ELISA protocol according to the manufacturer’s instruc-
tions (DBD00; R & D Systems, Europe).
IGT. For this computer-administered task, participants
were asked to draw from four decks of cards. Each deck
consisted of randomly distributed cards with differing
amount of gains and penalties, adding up to a pre-set net
outcome. Two decks contained cards with low levels of
gains (e.g. $50) and penalties (e.g. $40), but their net
outcome was favorable (e.g. $100); the other two decks
consisted of cards with high gains (e.g. $100) but even
higher penalties (e.g. $200), so that their net outcome was
unfavorable (e.g. −$250).
All participants were instructed to try to earn as much
money as possible by drawing cards one at a time from a
deck of their choice. They were informed that some decks
were more advantageous than others but were not told the
composition of the decks. The entire IGT procedure was
completed upon drawing 100 cards.
Three IGT indices were derived with high scores indi-
cating effective strategic thinking: net total score, calculated
as the number of draws from advantageous decks minus that
from the disadvantageous decks (Barry & Petry, 2008);
proportion of advantageous deck selections from the total
number of cards; and improvement score, calculated by
subtracting the net score of the ﬁrst block of 20 cards from
that of the last block.
Statistical analyses
An analysis of covariance, with age, body-mass index
(BMI), and BDI scores entered as covariates, was used to
compare serum BDNF levels of the patients and controls.
The correlation between serum BDNF levels and the sever-
ity of GD based on PGSI scores in the patient group was
examined using Pearson partial-correlation analysis, by
controlling for age, BDI scores, and the duration of problem
gambling. Finally, the association between serum BDNF
levels and IGT performance was analyzed using the same
method. All data are presented as means ± standard devia-
tions (SD). The signiﬁcance level was set at p < 0.05. All
statistical analyses were conducted using SPSS, version
18.1 (Chicago, Illinois, USA).
Ethics
The Ethical Committee of the Eulji University, Korea,
approved this study protocol. In accordance with the Dec-
laration of Helsinki, all subjects were advised about the
procedures and signed the written informed consent prior to
participation.
RESULTS
The demographic data, gambling-related clinical variables,
and IGT indices are listed in Table 1. The mean serum BDNF
levels were signiﬁcantly increased in the patients with GD
(29051.44 ± 6237.42 pg/ml) compared to healthy controls
(19279.67 ± 4375.58 pg/ml, p < 0.0001) (Figure 1). We also
found a signiﬁcant correlation between serum BDNF levels
and PGSI scores (r = 0.56, p < 0.05) after controlling for
age, BDI scores, and the duration of problem gambling.
Serum BDNF levels were also signiﬁcantly negatively
correlated with the IGT improvement scores (r = –0.48,
p < 0.05), but not with IGT total net scores (r = –0.163, n.s.)
or advantageous proportion (r = –0.19, n.s.).
DISCUSSION
In this study, we found signiﬁcantly higher serum BDNF
levels among patients with GD than in healthy controls, as
well as a positive association between the serum BDNF
levels and severity of GD. Such ﬁndings are in partial
agreement with previous studies showing that serum
BDNF levels increased in GD (Angelucci et al., 2013;
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Geisel et al., 2012), although these studies present different
results regarding the association between serum BDNF
levels and severity of GD. Such discrepancies might be
related to external factors that affect serum BDNF levels,
including BMI, depression, and other confounding factors
(Piccinni et al., 2008). Together with these two previous
studies (Angelucci et al., 2013; Geisel et al., 2012), our
ﬁndings suggest that behavioral addictions might be asso-
ciated with neural plasticity similar to alterations observed
in SUDs. Increased serum BDNF levels might then repre-
sent a compensatory mechanism to normalize dopaminergic
transmission in VTA and the NAc (Geisel et al., 2012).
Another plausible explanation is that increased BDNF plays
a role in neuroprotective and stress-preventive processes in
patients with GD, especially during stressful situations, as
found in those with SUDs (Bhang, Choi, & Ahn, 2010;
Geisel et al., 2012).
Although a recent study (Kang et al., 2010) showed that
the BDNF Val66Met polymorphism may affect decision-
making performance as measured by IGT, to the best of our
knowledge, our study is the ﬁrst to demonstrate a signiﬁ-
cant association between serum BDNF levels and IGT
improvement scores. The IGT improvement score particu-
larly reﬂects learning processes based on the evaluation of
choice-outcomes of rewards and penalties leading to long-
term gain or loss. This learning involves discounting imme-
diate rewards while formulating an advantageous strategy
based on previous cumulative outcomes. A recent study
(Kräplin et al., 2014) found that problem gamblers showed
higher overall impulsivity compared to healthy controls and
higher ‘choice impulsivity’ compared to a Tourette syn-
drome group, but similar levels of impulsivity as an alcohol-
dependent group. Higher BDNF concentration has also been
positively correlated with higher impulsivity in PTSD
patients (Martinotti et al., 2015) suggesting that impulsive-
ness may be associated with greater BDNF expression.
Additionally, in murine models, BDNF has been implicated
in the actions of serotonergic neurons, particularly in
Table 1. Demographic data, BDI, BDNF, IGT index, and GD related variables
GD (n = 21) Control (n = 21)
Variable M (SD) M (SD) Test statistics p-value
Age 40.52 (12.35) 39.29 (3.96) t = 0.438 0.664
BMI 25.17 (3.42) 22.54 (2.43) t = 2.873 < 0.01
BDI 18.48 (11.78) 4.10 (3.03) t = 5.420 < 0.0001
BDNF (pg/ml) 29051.44 (6237.42) 19279.67 (4375.58) t = 5.877 < 0.0001
IGT total net score 9.14 (21.81)
Advantageous proportion 0.55 (0.11)
IGT improvement score 2.86 (5.08)
CPGI-PGSI 20.10 (4.79)
GD duration (years) 8.14 (5.30)
No. of gambling methods* χ2 = 0.048 0.827
One 10 (47.6%)
Multiple (two or more) 11 (52.4%)
GD type* χ2 = 2.333 0.127
Action type 14 (66.7%)
Escape type 7 (33.3%)
Gambling categorya* χ2 = 2.333 0.127
Strategic 7 (33.3%)
Analytic 14 (66.7%)
Note: *Marked variables are categorical variables with N (%), therefore Chi-square test was used. GD: gambling disorder; BMI: body mass
index (weight / height2); BDI: Beck Depression Inventory; BDNF: brain-derived neurotrophic factor; IGT total net score: total advantageous
deck counts minus total disadvantageous deck counts; Advantageous proportion: advantageous deck counts / total card selection (100 cards);
IGT improvement score: block5 IGT net score minus block1 IGT net score; CPGI-PGSI: Canadian Problem Gambling Index-Problem
Gambling Severity Index.













Figure 1. The mean serum BDNF levels were signiﬁcantly
increased in the patients with gambling disorder (29051.44 ±
6237.42 pg/ml) compared to healthy controls (19279.67 ±
4375.58 pg/ml, p < 0.0001) by ANCOVA with age, BMI, and the
scores of BDI as covariates. The box plots show the median
and quartiles, and the whisker caps of the box plots show the
mean 5th and 95th percentile values.; * Indicates statistical
signiﬁcance (F = 12.11, p ≤ 0.001)
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aggression and impulsivity (Lyons et al., 1999). Both BDNF
and serotonin regulate the development and plasticity of
neural circuits in mood disorders (Martinowich & Lu,
2008). In humans, BDNF Val66Met polymorphism in
schizophrenia patients has been associated with aggressive
behavior (Spalletta et al., 2010), while serotonin has been
found to play a signiﬁcant role in learning and memory
(Meneses & Liy-Salmeron, 2012). Taken together, our
results suggest that BDNF may also play a role in learning
processes, and that the relationship between BDNF and
serotonin needs to be further examined.
Some limitations of this study warrant discussion; our
sample size was modest and contained only male GD
patients, thus limiting the generalizability of our results.
Serum BDNF levels were examined rather than central
nervous system BDNF levels. Although BDNF regulation
in peripheral blood is still poorly understood, peripheral
concentrations are widely used as a mirror of the same brain
parameter (Yamada et al., 2002). Because BDNF is known
to cross the blood-brain barrier in both directions, a sub-
stantial part of peripheral BDNF might originate from
neuronal cells of the central nervous system (Karege,
Schwald, & Cisse, 2002). At the present, the relationships
among BDNF, severity of disorder, and decision-making in
GD patients are not clearly delineated, and future studies
should consider these limitations in their designs for a better
understanding of such relationships. In addition, we did not
take into account personality factors in our study design.
Previous studies have suggested relationships between path-
ological gambling and personality characteristics such as
novelty-seeking and self-directness (Jiménez-Murcia et al.,
2010; Martinotti et al., 2006), but consensus on the rela-
tionship between the BDNF levels and these personality
traits has yet to be reached due to inconsistent results
(Maclaren, Fugelsang, Harrigan, & Dixon, 2011). The re-
sults of our study should be interpreted carefully in light of
such a limitation.
CONCLUSIONS
The ﬁndings of this study support the hypothesis that serum
BDNF levels may serve as a candidate biomarker for neural
plasticity and the severity of GD in these patients. Further-
more, heightened serum BDNF levels in GD may indicate
poor decision-making performance, a characteristic feature
of SUDs. This study, therefore, is a meaningful addition to
the growing body of research supporting the common
neurobiological underpinnings of SUDs and GD.
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